Search Result

Results for "

MDD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Adrenergic Receptor (1) Akt (3) AMPK (3) Apoptosis (3) Autophagy (3) Calcium Channel (3) COX (3) Dopamine Receptor (1) Dopamine Transporter (1) Interleukin Related (3) Isotope-Labeled Compounds (1) mGluR (3) MMP (3) Monoamine Oxidase (1) Monoamine Transporter (1) mTOR (3) NF-κB (3) p38 MAPK (3) PI3K (3) PKC (3) Reactive Oxygen Species (ROS) (3) Reference Standards (2) Serotonin Transporter (7) STAT (3) Thyroid Hormone Receptor (1) Trk Receptor (3)
By Research Areas:	Cancer (4) Inflammation/Immunology (3) Neurological Disease (16)

By Targets:

5-HT Receptor (4)

Adrenergic Receptor (1)

Akt (3)

AMPK (3)

Apoptosis (3)

Autophagy (3)

Calcium Channel (3)

COX (3)

Dopamine Receptor (1)

Dopamine Transporter (1)

Interleukin Related (3)

Isotope-Labeled Compounds (1)

mGluR (3)

MMP (3)

Monoamine Oxidase (1)

Monoamine Transporter (1)

mTOR (3)

NF-κB (3)

p38 MAPK (3)

PI3K (3)

PKC (3)

Reactive Oxygen Species (ROS) (3)

Reference Standards (2)

Serotonin Transporter (7)

STAT (3)

Thyroid Hormone Receptor (1)

Trk Receptor (3)

By Research Areas:

Cancer (4)

Inflammation/Immunology (3)

Neurological Disease (16)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14262

Vilazodone 4 Publications Verification EMD 68843; SB659746A	5-HT Receptor Serotonin Transporter	Neurological Disease
Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-160207

Elunetirom MA-JD21; ABX-002	Thyroid Hormone Receptor	Neurological Disease
Elunetirom (MA-JD21 )is a TR-β selective CNS-penetrant TR-β agonist prodrug and can be used for study of major depressive disorder (MDD) .

HY-15413A

Edivoxetine hydrochloride LY 2216684 hydrochloride	Serotonin Transporter	Neurological Disease
Edivoxetine (LY 2216684) hydrochloride is a potent and selective norepinephrine reuptake inhibitor. Edivoxetine hydrochloride can be used for the study of major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD) .

HY-19907

Liafensine BMS-820836	Monoamine Transporter Dopamine Transporter Serotonin Transporter	Neurological Disease
Liafensine (BMS-820836) is a triple monoamine reuptake inhibitor (TRI), that inhibits dopamine transporter, serotonin transporter and norepinephrine transporter, with IC₅₀s of 5.67, 1.08 and 7.99 nM, respectively. Liafensine exhibits antidepressant activity .

HY-148417

ZZL-7	Serotonin Transporter	Neurological Disease
ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD) .

HY-14262S1

Vilazodone-d8 hydrochloride EMD 68843-d8; SB659746A-d8	5-HT Receptor Serotonin Transporter Isotope-Labeled Compounds	Neurological Disease
Vilazodone-d₈ hydrochloride is deuterated labeled Vilazodone (HY-14262). Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-14262R

Vilazodone (Standard) EMD 68843 (Standard); SB659746A (Standard)	Reference Standards 5-HT Receptor Serotonin Transporter	Neurological Disease
Vilazodone (Standard) is the analytical standard of Vilazodone. This product is intended for research and analytical applications. Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-15413

Edivoxetine LY 2216684	Adrenergic Receptor	Neurological Disease
Edivoxetine (LY 2216684) is a potent and selective norepinephrine reuptake inhibitor. Edivoxetine can be used for the study of major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD) .

HY-154977

ETAP	Monoamine Oxidase	Neurological Disease Cancer
ETAP is a MAO-A and MAO-B inhibitor. ETAP has antidepressant-like effect. ETAP can be used for research of major depressive disorder .

HY-169394

5-HT1AR agonist 2	5-HT Receptor Serotonin Transporter Dopamine Receptor	Neurological Disease
5-HT_1AR agonist 2 (Compound 4f) is a 5-HT_1A receptor agonist (K_i: 10.0 nM). 5-HT_1AR agonist 2 also binds to the SERT, D₂ receptor and 5-HT₆ receptor (K_i: SERT, 2.8 nM; D₂, 23 nM; 5-HT₆, 192 nM). 5-HT_1AR agonist 2 is stabilized in microsomes and induces hypothermia in mice .

HY-110255

AZD 2066 1 Publications Verification	mGluR Calcium Channel Trk Receptor	Neurological Disease
AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease .

HY-110255A

AZD 2066 hydrate	mGluR Calcium Channel Trk Receptor	Neurological Disease
AZD-2066 hydrate is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 hydrate activates the BDNF/trkB signaling pathway. AZD 2066 hydrate can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease .

HY-110255B

AZD-2066 hydrochloride	mGluR Calcium Channel Trk Receptor	Neurological Disease
AZD-2066 hydrochloride is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 hydrochloride activates the BDNF/trkB signaling pathway. AZD 2066 hydrochloride can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease .

HY-N0735

Phellodendrine chloride 1 Publications Verification	Autophagy Apoptosis AMPK mTOR STAT Interleukin Related PKC p38 MAPK NF-κB COX Reactive Oxygen Species (ROS) PI3K Akt MMP	Neurological Disease Inflammation/Immunology Cancer
Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .

HY-N0427

Phellodendrine	Akt NF-κB AMPK mTOR PKC STAT Interleukin Related p38 MAPK COX Reactive Oxygen Species (ROS) Apoptosis Autophagy PI3K MMP	Neurological Disease Inflammation/Immunology Cancer
Phellodendrine is an orally active plant alkaloid. Phellodendrine inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway .

HY-N0735R

Phellodendrine chloride (Standard)	Reference Standards Autophagy mTOR AMPK Apoptosis STAT Interleukin Related PKC p38 MAPK NF-κB COX Reactive Oxygen Species (ROS) PI3K Akt MMP	Neurological Disease Inflammation/Immunology Cancer
Phellodendrine chloride (Standard) is the analytical standard of Phellodendrine chloride (HY-N0735). Phellodendrine chloride is an orally active plant alkaloid. Phellodendrine chloride inhibits the proliferation of KRAS-mutated pancreatic cancer cells by suppressing macropinocytosis and glutamine metabolism, inducing ROS accumulation and mitochondrial apoptosis. Phellodendrine chloride promotes autophagy by activating the AMPK/mTOR pathway, alleviating intestinal damage in ulcerative colitis. Phellodendrine chloride can alleviate gouty arthritis by inhibiting the IL-6/STAT3 signaling pathway. Phellodendrine chloride suppresses allergic reactions by altering the conformation of MRGPRB3/MRGPRX2 protein, thereby inhibiting the activation of PKC and subsequent downstream MAPK and NF-κB signaling. Phellodendrine chloride inhibits the AKT/NF-κB pathway and down-regulates the expression of COX-2, thereby protecting zebrafish embryos from oxidative stress. Phellodendrine chloride has an anti-major depressive disorder (MDD) effect by down-regulating CHRM1, HTR1A, and the PI3K/Akt signaling pathway.

Cat. No.	Product Name

HY-L108

Antidepressant Compound Library	2,459 compounds
Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors. Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent. MCE offers a unique collection of 2,459 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Antidepressant Compound Library

2,459 compounds

Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors.

Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent.

MCE offers a unique collection of 2,459 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Cat. No.	Product Name	Category	Target	Chemical Structure